Intellia Therapeutics (NTLA) Stock May Be Fully Priced Despite Its 92% Slide

Intellia Therapeutics stock has rebounded over the past year, yet its longer term track record and current valuation checks point to a much less flattering picture. The current market pricing appears rich compared with the broader fundamentals scorecard and the long run return profile.

• Over the past 5 years, Intellia Therapeutics shareholders have seen the stock fall about 92%, which puts a spotlight on how much long term value the market believes is still on the table.
• Future progress on bringing its gene editing pipeline closer to commercial cash flows can support the valuation. However, ongoing development risk and potential future funding needs may weigh on how much investors are willing to pay upfront.
• The stock screens as overvalued on market multiples and earns a low overall valuation score. Only 2 of 6 checks suggest it is attractively priced, which means this is not a clear bargain on the broader measures 2.

The issue now is whether the recent recovery in Intellia Therapeutics shares leaves enough upside potential to compensate for the risks investors are taking on.

Balance Intellia Therapeutics' sharp 5 year decline and recent rebound by comparing it with hand picked 51 high quality undervalued stocks that combine stronger fundamentals and more modest pricing.

Has Intellia Therapeutics Run Too Far on Sales?

P/S is often the cleaner yardstick for Intellia Therapeutics because the company is still loss making, so earnings-based ratios such as P/E do not tell you much about what investors are paying for its current revenue base.

On this measure, Intellia Therapeutics trades at about 31.1x P/S, which is above the Biotechs industry average of 13.4x and also higher than the peer group average of 22.1x. The tailored fair ratio from the model is 0.1x, which is far below the current level. That very low figure reflects how heavily the framework penalises Intellia Therapeutics for its losses, risk profile and reliance on future expectations. It is therefore better interpreted as a strong warning signal rather than a precise target multiple.

Taken together, the current P/S indicates that Intellia Therapeutics stock appears expensive on this market multiple approach.

See what the numbers say about this price — find out in our valuation breakdown.

The Intellia Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Intellia Therapeutics leaves off by spelling out which future paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Rather than relying on a single multiple or model result, each narrative lays out the assumptions behind its view of fair value so you can compare them with actual outcomes over time.

One of the top community narratives on Intellia Therapeutics: 76% undervalued

"The FDA clinical hold on nex-z after a patient death and Grade 4 liver enzyme elevations introduces meaningful regulatory and clinical uncertainty for one of Intellia Therapeutics' key late stage programs..."

Read one of the top narratives on Intellia Therapeutics

Do you think there's more to the story for Intellia Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Intellia Therapeutics screens as overvalued on market multiples, with a wide gap between its P/S ratio and sector benchmarks. The broader valuation checks are weak, which suggests the current price already bakes in demanding expectations for future execution and funding. For you as an investor, the key question is whether Intellia Therapeutics can convert its pipeline into durable revenue in a way that eventually justifies this premium, or whether the market is paying too much upfront for that possibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com